Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
CONCLUSION: RAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.TRIAL REGISTRATION: INPLASY registration number INPLASY2022120023.PMID:38619719 | DOI:10.1007/s12325-024-02838-5
Source: Adv Data - Category: Epidemiology Authors: Xiaotian Zhang Li Zhou Chan Zhou Lin Shen Source Type: research
More News: Abraxane | Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Epidemiology | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Japan Health | South Korea Health | Study | Toxicology